GLOBEALERT
Business● Low23m ago · Nov 16, 2026, 5:00 AM

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

GlobeAlert Desk · curated from South China Morning Post · East Asia

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global...

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
1 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Business

Not flagged as developing.

East Asia theater · last 7 days
steady · 2 in the last 24h
638
events logged
86
risk index / 100
Wildfires 600Rocket Launches 10Attacks & Assaults 10Prediction Markets 6Kidnappings 4
  • Second jury cant agree on underworld murder chargeAttacks & Assaults · Japan · 3h ago
  • Black clover season 2 episode 7 recap ending explained who killed megicula and what happened to gajaAttacks & Assaults · Japan · 8h ago
  • Mother of japanese abducted by n. korea urges resolution 49 years onKidnappings · North Korea · 19h ago
See the theater on the live map →

More in Business